Allergan’s $639m purchase of Vitae Pharmaceuticals gives the company an oral drug for a key dermatology indication and the potential to address other autoimmune disorders consistent with its focus on seven key therapeutic areas.
Its $639m acquisition of Vitae Pharmaceuticals Inc. at first glance seems to be an obvious buy for Allergan PLC, since dermatology is one of the company’s seven key therapeutic areas, but Vitae’s lead drug candidate could open the door to new inflammation and autoimmune disease programs adjacent to Allergan’s existing areas of interest.
Vitae’s lead drug candidate is the retinoic acid receptor-related orphan receptor gamma (RORγt) inhibitor VTP-43742, which is in Phase II...
The Swiss pharma company is rebalancing the portfolio, emphasizing best-in-class drugs and moving into new areas like cardiovascular and metabolic disease.
Merck’s immuno-oncology blockbuster was the world’s best-selling drugs by revenues for the second year in a row, with an almost $12bn lead over its closest rival, Novo Nordisk’s GLP-1 drug Ozempic.
Francesco Hofmann, head of R&D at the mid-sized French group, tells Scrip that its strategy of not playing in the spaces that are dominated by big pharma is paying off.
Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.
Novartis’s APMA chief outlines the company’s tailored approach to deliver long-term outcomes, novel access solutions via innovative financing options and shape the CVD disease ecosystem in the extraordinarily diverse region. Partnering to build AI infrastructure is another key prong.
A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.
